



# Tutorial

## NOACs

*From the Editorial desk*

### 1. What does NOAC stand for?

Non Vitamin K antagonist Oral Anti Coagulants.

The drugs in this class which are sometimes used in this country are,

- dabigatran
- rivaroxaban
- apixaban.

Dabigatran is a thrombin inhibitor. Rivaroxaban and apixaban are factor Xa inhibitors.

### 2. Can NOACs be used for atrial fibrillation complicating mitral stenosis?

No.  
NOACs are not authorized for used in hemodynamically significant valvular diseases.

### 3. Can NOACs be used for anti-coagulation for prosthetic valves?

No.  
(See answer for question 4).

### 4. For what indications can NOACs be used?

- Non valvular atrial fibrillation.
- Prevention of venous thrombosis and embolism after knee/hip joint replacement.
- Deep vein thrombosis of lower limbs.  
(Thrombosis of cerebral veins, portal vein, splenic vein, upper torso veins are not indications for NOACs).

### 5. Need the renal and hepatic function be assessed before using NOACs?

Yes.

Do not use in the following:

- Hepatic insufficiency of Child-Pugh Category B
- Creatinine clearance < 15-30 mL/ min by Cockcroft- Gault equation.

### 6. How do you switch from warfarin sodium to NOACs?

- Adjust warfarin sodium dosage until the INR is <2.5
- Once this INR is reached commence NOACs.

### 7. How do you switch from NOACs to warfarin sodium?

Start on warfarin sodium 5 mg while on NOACs.

Do INR daily.

Once INR reaches 2, omit NOACs. Repeat INR in 3 days to ensure INR is in the therapeutic range.



**8. If a patient on NOACs has a non-life threatening major bleed, what is the management?**

Omit NOACs and observe.

The bleeding will stop in 12-24 hours if renal function is OK.

In the presence of renal dysfunction, normalization may take 48 hours.

**9. If a patient on NOACs has life threatening bleeding, what is the management?**

Reverse action as follows:

Dabigatran – Idarucizumab 2.5 mg iv two doses.

(The two doses 15 minutes apart)

Factor Xa inhibitors –  
Prothrombin concentrate 50u/kg.

**10 A patient on NOACs has had a significant gastric bleed. What is the management?**

- i. Manage the gastric bleed as usual.
- ii. Observe for 7 days.
- iii. If the risk of stroke persists and out weighs the risk of recurrent bleed, restart NOACs after 7 days. Use a lower dosage if the dose is approved for the indication.

**11. If a patient on NOACs has to undergo surgery, what is the management?**

- i. Withhold the NOACs for 12-48 hours.
- ii. Bridging heparin is usually not required. But if so required by the cardiologist, UFH can be started 24 hours after stopping NOAC.
- iii. If LMWH is to be commenced, check the Cr Cl. If <25ml/mt wait for 48 hours before commencement.

**12. If a patient already on NOACs develops an acute coronary syndrome what is the management?**

- i. PCI is the safest mode of therapy. Use a radial approach. Primary PCI is allowed.
- ii. If not very high risk or high risk unstable angina, wait for 24 hours and perform PCI as appropriate.
- iii. Antiplatelet agents may be given along with PPIs.

**13. How do you administer anti platelet agents along with NOACs?**

- i. Patients with acute coronary syndrome who have undergone PCI- stenting, need dual anti platelet therapy. These patients may need “triple therapy” (i.e. NOAC + aspirin + clopidogrel) for three months.
- ii. Subsequently omit aspirin and continue on dual therapy (i.e. NOAC + clopidogrel) for 1 year.
- iii. After one year continue only on NOAC.

**14. What is the management if a patient on NOACs develops an ischemic stroke?**

- i. If the last intake of NOAC is >48 hours, thrombolysis may be permitted.
- ii. Endovascular therapy is ideal if available.
- iii. If NOAC has been ingested recently, reverse action of NOAC (as in question 9) and administer thrombolytic agent.
- iv. Restart NOAC 2 weeks after the stroke.

**15. What drugs must not be co – prescribed with NOACs?**

- i. Rifampicin
- ii Anti fungal agents
- Iii Dexamethasone
- iv HIV protease inhibitors